As of 2025-10-23, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -8.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 1,175.06 mil USD. NKTR's TTM EBITDA according to its financial statements is -136.89 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.4x - 12.1x | 9.3x |
| Forward P/E multiples | 10.1x - 13.3x | 11.4x |
| Fair Price | (72.84) - (87.38) | (74.31) |
| Upside | -217.9% - -241.4% | -220.3% |
| Date | EV/EBITDA |